Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma

Journal of Dermatology

Volumn 40, Issue 12, 2013, Pages 973-979

  Zhu, Li ^a   Ito, Takamichi ^a   Nakahara, Takeshi ^a   Nagae, Konosuke ^a   Fuyuno, Yoko ^a   Nakao, Masayoshi ^a   Akahoshi, Maki ^a   Nakagawa, Rieko ^a   Tu, Yating ^b   Uchi, Hiroshi ^a   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ezrin; malignant melanoma; receptor for advanced glycation end products; S100P

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; EZRIN; MEMBRANE PROTEIN; PROTEIN S100P; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HAIR FOLLICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; NEVUS CELL; PIGMENTED NEVUS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEBACEOUS GLAND; SKIN METASTASIS; SWEAT GLAND; UPREGULATION;

EZRIN; MALIGNANT MELANOMA; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; S100P;

CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; CYTOSKELETAL PROTEINS; HUMANS; MELANOMA; NEOPLASM PROTEINS; NEVUS, PIGMENTED; RECEPTORS, IMMUNOLOGIC; SKIN NEOPLASMS; UP-REGULATION;

EID: 84890425750     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12323     Document Type: Article

References (34)

1. Salama I, Malone PS, Mihaimeed F, Jones JL,. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008; 34: 357-364.
2. Lukanidin E, Sleeman JP,. Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol 2012; 22: 216-225.
3. Becker T, Gerke V, Kube E, Weber K,. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 1992; 207: 541-547.
4. Wang G, Platt-Higgins A, Carroll J, et al,. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006; 66: 1199-1207.
5. 2)/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol Ther 2010; 10: 1056-1066.
6. Barry S, Chelala C, Lines K, et al,. S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Clin Exp Metastasis 2013; 30: 251-264.
7. Zhu L, Okano S, Takahara M, et al,. Expression of S100 protein family members in normal skin and sweat gland tumors. J Dermatol Sci 2013; 70: 211-219.
8. Goto Y, Ferrone S, Arigami T, et al,. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 2008; 14: 3401-3407.
9. Jiang H, Hu H, Tong X, Jiang Q, Zhu H, Zhang S,. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. J Cancer Res Clin Oncol 2012; 138: 1-9.
10. Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ,. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010; 17: 2232-2252.
11. Leclerc E, Heizmann CW, Vetter SW,. RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen Physiol Biophys 2009; 28 Spec No Focus: F65-F75.
12. Luo Y, Zheng C, Zhang J, et al,. Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene 2012; 31: 306-321.
13. Buckley ST, Medina C, Kasper M, Ehrhardt C,. Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011; 300: L548-L559.
14. Curto M, McClatchey AI,. Ezrin, a metastatic detERMinant? Cancer Cell 2004; 5: 113-114.
15. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L,. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 2007; 27: 3051-3058.
16. Sedaghat F, Notopoulos A,. S100 protein family and its application in clinical practice. Hippokratia 2008; 12: 198-204.
17. Weide B, Elsässer M, Büttner P, et al,. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 2012; 107: 422-428.
18. Yoshimura C, Miyafusa T, Tsumoto K,. Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells. Bioorg Med Chem 2013; 21: 1109-1115.
19. Zimmer DB, Lapidus RG, Weber DJ,. In vivo screening of S100B inhibitors for melanoma therapy. Methods Mol Biol 2013; 963: 303-317.
20. Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM,. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004; 17: 990-997.
21. Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O,. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 1997; 74: 464-469.
22. Dukhanina EA, Lukyanova TI, Romanova EA, Dukhanin AS, Sashchenko LP,. Comparative analysis of secretion of S100A4 metastatic marker by immune and tumor cells. Bull Exp Biol Med 2008; 145: 78-80.
23. Wang Q, Zhang YN, Lin GL, et al,. S100P, a potential novel prognostic marker in colorectal cancer. Oncol Rep 2012; 28: 303-310.
24. Cai XY, Lu L, Wang YN, et al,. Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. Atherosclerosis 2011; 217: 536-542.
25. Leibold JS, Riehl A, Hettinger J, Durben M, Hess J, Angel P,. Keratinocyte-Specific Deletion of the Receptor RAGE Modulates the Kinetics of Skin Inflammation In Vivo. J Invest Dermatol 2013; 133: 2400-2406.
26. Turovskaya O, Foell D, Sinha P, et al,. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
27. Gebhardt C, Riehl A, Durchdewald M, et al,. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-285.
28. Koltzscher M, Neumann C, König S, Gerke V,. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 2003; 14: 2372-2384.
29. Austermann J, Nazmi AR, Müller-Tidow C, Gerke V,. Characterization of the Ca2+-regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem 2008; 283: 29331-29340.
30. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O,. Ezrin in primary cutaneous melanoma. Mod Pathol 2005; 18: 503-510.
31. Mäkitie T, Carpén O, Vaheri A, Kivelä T,. Ezrin as a prognostic indicator and its relationship to tumor characteristics in c malignant melanoma. Invest Ophthalmol Vis Sci 2001; 42: 2442-2449.
32. Piérard GE, Piérard-Franchimont C, Delvenne P,. Malignant melanoma and its stromal nonimmune microecosystem. J Oncol 2012; 2012: 584219. doi: 10.1155/2012/584219.
33. Kato H, Liao Z, Mitsios JV, et al,. The primacy of β1 integrin activation in the metastatic cascade. PLoS ONE 2012; 7 (10): e46576. doi: 10.1371/journal.pone.0046576.
34. Jung Y, McCarty JH,. Band 4.1 proteins regulate integrin-dependent cell spreading. Biochem Biophys Res Commun 2012; 426: 578-584.